TCM
TRVI icon

Tang Capital Management’s Trevi Therapeutics TRVI Stock Holding History

Tang Capital Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-300,000
Closed -$402K – 132
2023
Q4 		$402K Buy
+300,000
New +$454K 0.04% 116

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Tang Capital Management's TRVI Position: Q1 2024 in Review

Tang Capital Management sold out of Trevi Therapeutics (TRVI) in Q1 2024, closing a stake of 300,000 shares — an estimated $402K sold.

Tang Capital Management first reported a position in TRVI in Q4 2023 and held it in 1 quarter. The position peaked at $402K in Q4 2023. 80 funds tracked by Wall St. Rank hold TRVI as of Q1 2024.

  • Tang Capital Management reported no remaining Trevi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 300,000 Trevi Therapeutics shares in Q1 2024, an estimated $402K.
  • Tang Capital Management first reported a position in Trevi Therapeutics in Q4 2023 and held it in 1 quarter.
  • Tang Capital Management's Trevi Therapeutics position peaked at $402K in Q4 2023.
  • 80 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.